Could T-cell immunotherapy be the answer to COVID-19?
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
List view / Grid view
Scientists from Singapore have argued that T-cell immunotherapy can be used to combat a range of infectious diseases, including COVID-19.
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
Researchers who administered an antibody to neutralise an OCD-associated protein in mice found it reduced their anxious behaviours.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.
A new method has been developed by researchers using chemical tools activated by light to influence lipid concentration in living cells.
A total of 21 COVID-19 research projects have been granted funding by the UK government, including vaccine and therapeutic development.
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
Researchers comparing the effects of SARS-CoV-2, SARS-CoV and MERS-CoV in cynomolgus macaques suggest they could be an effective animal model for testing COVID-19 therapeutics.
An Ebola vaccine that has been tested in animals could potentially be used to neutralise four species of the virus, say the researchers.
Researchers testing 2-deoxy-D-glucose in mouse models of ovarian cancer report that the compound significantly improves the effectiveness of the chemotherapy drug, carboplatin.
Researchers who developed modified proteins say this could be used in the fight against COVID-19, by tackling cytokine storms.
A collaboration between academia and industry has produced an assay and new screening technique which utilises directed evolution for the discovery of antibody-based drugs.
A study has shown that two products of bacterial bile metabolism boost the conversion of precursor T cells into peripheral Tregs, which suppress chronic inflammation in the colon.